Business
Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025
Company outlines continued progress executing operational transformation and growth strategy across its dental and medical segmentsROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company’s transform
About this update from Milestone Scientific, Inc.
[{"type":"image","alt":"Milestone Scientific, Inc.","displaySize":"","headline":null,"caption":"Milestone Scientific, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/exjbRkdU8va83bSGZUweuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11","width":300,"height":65}},"lazy":false},{"type":"text","content":"Company outlines continued progress executing operational transformation and growth strategy across its dental and medical segments","length":131,"tagName":"p"},{"type":"text","content":"ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company’s transformation and growth initiatives.","length":398,"tagName":"p"},{"type":"text","content":"Eric Hines, Chief Executive Officer of Milestone Scientific, stated, “During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operational restructuring, we reduced third-quarter operating expenses by over half a million dollars compared to the same period last year. At the same time, we delivered stable revenue performance while continuing to strengthen our underlying business fundamentals.”","length":552,"tagName":"p"},{"type":"text","content":"“Within our dental segment, we continued to expand our direct sales programs in North America and continued securing new international registrations for our STA® Single Tooth Anesthesia System. We also enhanced our omnichannel digital marketing strategy to drive broader brand visibility and recurring e-commerce sales. On the medical side, we are encouraged by growing utilization and recurring revenue from CompuFlo® disposables, as well as increasing interest from hospitals and international distributors.”","length":510,"tagName":"p"},{"type":"text","content":"“In parallel,...